Forest Laboratories (NYSE:FRX) is facing another delay where the approval of one of its pipeline candidates is concerned. The company and its partner, Ironwood Pharmaceuticals, Inc. (IRWD) recently announced that the FDA has extended the review period for their new drug application for linaclotide.
Forest Labs and Ironwood are looking to get linaclotide approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The FDA has extended the review … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards